央视网消息（焦点访谈）：2025年中央经济工作会议指出，建设北京（京津冀）、上海（长三角）、粤港澳大湾区国际科技创新中心。北京和上海一直在建 设国际科技创新中心。北京连续9年稳居自然指数—科研城市全球榜首，研发投入强度稳定在6%左右。上海已建、在建和规划建设的重大科技基础设施有20 个，科创板上市企业总市值居全国首位，成效显著。那么为什么还要将范围扩大到京津冀和长三角？扩围，是简单的地理版图的延伸，还是要破解创新发展 的瓶颈？未来将释放什么样的新动能呢？来看记者调查。 在北京精雕集团的车间里，一次看似不可能的挑战正在进行。工程师操控机床，要在一枚蛋壳厚度不足0.5毫米的生鸡蛋上，正反两面分别刻下"焦点访 谈"和"京津冀"几个字。能完成这样精细的雕刻，奥秘就在于机床拥有"眼睛"和"大脑"。它能自动探测每个鸡蛋独特的曲面，并调整雕刻路径。正是这种控 制能力，让它足以胜任航空发动机叶片、精密医疗部件等高端产品的制造。这套完全自主研发的高精密数控机床，实际就是京津冀协同发展的成果。 北京精雕集团副总裁胡宇川："我们在北京精雕的总部完成了机床结构数控系统和工业软件的研发和设计。在天津精雕完成主轴和刀库的设计和生产，最终 ...

（来源：辽宁日报） 转自：辽宁日报 "政府工作报告提出强化'一老一小'服务，这对我们是鼓舞，更是沉甸甸的责任。"省政协委员、沈阳河 马健康管理有限公司总裁柯东月难掩激动。作为深耕儿童健康管理领域的一线实践者，柯东月第一时间 在公司内传达了省两会精神，"孩子在哪，我们的服务就延伸到哪。"新的一年，他将带领团队主动走进 幼儿园开展常态化健康服务，计划每年度覆盖20家幼儿园，把骨龄检测、脊柱侧弯早筛、哮喘预警等专 业服务精准送到孩子身边。全力守好"15分钟健康服务圈"，以标准化筛查流程、科学化干预方案赢得家 长信赖，切实为儿童健康成长保驾护航。 省人大代表、省政协委员一致表示，要解放思想、开拓创新，鼓足干劲、真抓实干，一起为梦想奋斗、 为幸福打拼，在推动新时代东北全面振兴取得新突破上勇于争先，奋力谱写中国式现代化辽宁篇章。 政府工作报告提出"提升科技创新效能，培育壮大新质生产力"，这让省政协委员、沈阳新松医疗科技股 份有限公司总经理黄勇深感责任在肩。他第一时间召开专题会议传达省两会精神，与团队共同谋划科技 赋能新举措。黄勇告诉记者："关键在于推动科技创新与产业创新深度融合。我们将依托辽宁本土科技 资源优势，全面提升 ...

Company Overview - Medtronic is a leading global healthcare solutions company operating in the medical technology sector, developing and manufacturing medical devices and therapies for various health conditions [1] - The company competes with major players in the healthcare industry, including Johnson & Johnson and Boston Scientific [1] Stock Performance - Medtronic's stock is currently priced at $101, reflecting a slight increase of 0.21, or 0.21%, from the previous trading session [2] - The stock has fluctuated between a low of $99.69 and a high of $101.59 today, with a yearly high of $106.33 and a low of $79.55 [2] - The market capitalization of Medtronic is approximately $129.5 billion, with a trading volume of 7.67 million shares today [2] Analyst Coverage - CICC initiated coverage on Medtronic with a bullish view, assigning it an "Outperform" grade, indicating a positive outlook on the company's future [5] - The current stock price of $101 shows investor confidence, aligning with the positive outlook from CICC [5] Investment Strategy - Eaton Vance Worldwide Health Sciences Fund has reduced its stake in Novo Nordisk AS by 49.25%, indicating a strategic shift in its investment approach [3] - The fund targets companies involved in healthcare product and service innovation, driven by growth potential associated with aging demographics and increasing global incomes [3] - The fund's strategy emphasizes acquiring reasonably priced stocks with long-term growth potential, which aligns with the bullish view on Medtronic [4]

Steel Partners Holdings on Wednesday publicly disclosed an unsolicited proposal to acquire a controlling stake in InMode Ltd. (NASDAQ:INMD) , offering shareholders a cash premium while criticizing the company's stock performance, capital allocation, and repeated guidance cuts.The stock is trading near the upper end of its 52-week range of $13.14-19.78, according to Benzinga Pro data.Steel Partners approached InMode about acquiring 51% of the company's outstanding shares at $18 per share. The offer represent ...

Financial Data and Key Metrics Changes - Blackstone reported GAAP net income for Q4 of $2 billion, with distributable earnings of $2.2 billion or $1.75 per common share, and declared a dividend of $1.49 per share [3][4] - For the full year, distributable earnings increased 20% to $7.1 billion, while fee-related earnings rose 9% to $5.7 billion, and management fees grew 12% to $8 billion [31][27] - Assets under management (AUM) increased 13% year-over-year to approximately $1.3 trillion, marking a new industry record [5][31] Business Line Data and Key Metrics Changes - The infrastructure platform grew 40% year-over-year to $77 billion, with over $4 billion raised in Q4 [16] - BXMA reported a gross return of 13% for 2025, with net inflows of $6.3 billion, the highest in nearly 15 years [17] - In credit, total assets managed reached $520 billion, up 15% year-over-year, with inflows exceeding $140 billion in 2025 [19] Market Data and Key Metrics Changes - Private wealth fundraising increased 53% year-over-year to $43 billion, contributing to a total AUM growth of 16% in this segment [4][22] - The insurance channel's AUM grew 18% year-over-year to $271 billion, with significant demand for private credit solutions [20][21] - The individual investor channel's AUM tripled over the past five years, exceeding $300 billion [22] Company Strategy and Development Direction - Blackstone is focusing on thematic areas such as digital infrastructure, private credit, and life sciences, with a strong emphasis on AI-driven investment opportunities [8][10] - The firm is well-positioned to benefit from the ongoing AI and power investment mega cycle, with nearly $200 billion of dry powder available for future investments [12][10] - The company anticipates a resurgence in capital markets activity, with IPO and M&A activities accelerating [10][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the firm's ability to navigate geopolitical uncertainties and a complex operating environment, citing strong operating fundamentals [7][12] - The outlook for 2026 is optimistic, with expectations for continued growth in management fees and net realizations, driven by a favorable investment environment [35][36] - Management highlighted the importance of investment performance, with strong returns across various funds, particularly in infrastructure and corporate private equity [31][33] Other Important Information - Blackstone's fundraising success has led to a significant increase in AUM, with a record level of inflows in Q4 [4][5] - The firm has executed multiple privatizations and investments, including a notable $18 billion acquisition in the medical technology sector [8][9] - The company is actively innovating in the private wealth market, expecting 2026 to be a busy year for product launches [24] Q&A Session Summary Question: What sectors and industries will you be leaning into for the record IPO pipeline? - The focus will be primarily on the corporate space, particularly energy and electricity sectors, with expectations for increased activity in India and some real estate opportunities [38] Question: How is AI being deployed across portfolio companies? - AI is enhancing productivity in software engineering and customer engagement, with early positive impacts observed in various operational areas [41] Question: What is the outlook for direct lending in both wealth and institutional markets? - Institutional confidence remains strong, while the wealth side has seen some redemptions; however, performance metrics are healthy, and inflows have been positive recently [46][48] Question: How does the firm plan to maintain growth and preserve culture as it scales? - The firm emphasizes a strong commitment to delivering for customers and maintaining a performance-driven culture, which is crucial as it continues to grow [62]

Core Insights - Advancements in artificial intelligence (AI) are significantly enhancing patient care, reducing healthcare costs, and improving outcomes in the medical technology industry [1] - Generative AI is transitioning from a conceptual promise to practical applications in medical technology [1] Industry Developments - AI is expediting all phases of research and development, including generative design, virtual testing, clinical trials, and regulatory documentation [2] - The FDA is promoting the development of innovative medical devices that incorporate AI [2] Company Performance: Tempus AI (TEM) - Tempus has seen a stock increase of 27.2% over the past year, while Doximity's stock has declined by 32.8% [6] - The company is developing advanced AI algorithms and diagnostic software, collaborating with Northwestern University's Abrams Center for Alzheimer's research [7] - Tempus has received two FDA 510(k) clearances for its cardiac imaging platform and ECG-Low EF software [8] - In Q3 2025, Tempus achieved positive adjusted EBITDA of $1.5 million, with gross profit rising to $209.9 million, a 98.4% year-over-year increase [11] - EPS for 2025 is projected to be a loss of 64 cents, reflecting a 59.5% improvement from 2024 [15] Company Performance: Doximity (DOCS) - Doximity is well-positioned for AI adoption, embedding AI across its workflows and benefiting from a recent acquisition of Pathway Medical Inc. [9][13] - The company reported a 55% adjusted EBITDA margin and a 39% net income margin in fiscal 2025, with $267 million in free cash flow [14] - EPS for fiscal 2026 is projected to be $1.56, indicating a 9.9% improvement from fiscal 2025 [16] Valuation Comparison - Tempus has a forward 12-month price-to-sales (P/S) ratio of 7.24, while Doximity's is 10.38, indicating Doximity is trading at a premium [17] Conclusion - Doximity appears better positioned than Tempus, with deep AI integration, strategic acquisitions, and strong profitability metrics [18] - Tempus is recognized for its expanding AI capabilities and recent profitability milestone, indicating long-term potential in precision medicine [19]

Fractyl Health (NasdaqGM:GUTS) Update Summary Company Overview - **Company**: Fractyl Health - **Industry**: Obesity treatment and metabolic disease management - **Product**: Revita, a one-time outpatient endoscopic procedure aimed at post GLP-1 weight maintenance Key Points from the Call Clinical Data and Study Results - The REMAIN-1 midpoint cohort pilot study presented data showing that Revita maintained weight six months after discontinuation of GLP-1s, indicating potential for a new therapeutic category in obesity [4][5] - Revita-treated patients experienced a 4.5% weight regain compared to 7.5% in the sham group, representing a significant reduction in post-GLP-1 rebound [11] - Patients with greater GLP-1-associated weight loss saw a 70% reduction in weight regain with Revita versus sham, with a p-value of 0.004 [14] - The study included 45 adults with obesity, achieving at least 15% total body weight loss on tirzepatide before randomization [9] - Safety profile remained stable with no new adverse events reported between the three-month and six-month follow-ups [17] Regulatory and Commercialization Path - Fractyl Health is in discussions with the FDA regarding reclassifying Revita under the De Novo pathway, which could streamline the regulatory review process [6][19] - The company anticipates FDA feedback on this request in Q2 2026 [19] - Plans for commercialization include leveraging FDA breakthrough device designation and CMS transitional pass-through mechanisms [20] - The potential market includes 2,000-4,000 endoscopy suites in the U.S., with an estimated capacity for 2-4 million procedures annually [22] Future Catalysts and Milestones - Upcoming milestones include completing randomization in the pivotal cohort by February 2026 and top-line pivotal data expected in the second half of 2026 [18][23] - The company is preparing for a potential FDA submission and CPT code filing, aiming for simultaneous implementation with FDA approval [20] Insights on Efficacy and Market Position - Revita is positioned as a potential backbone therapy in obesity, particularly for patients at high risk of weight regain after GLP-1 therapy [8] - The data suggests that Revita may help maintain a lower body weight set point, supported by improvements in cardiometabolic parameters and reduced food cravings [16][17] - The pivotal study is designed to mirror the REMAIN-1 cohort, ensuring consistency in inclusion and exclusion criteria [18] Additional Considerations - The study's design intentionally focused on patients with significant weight loss on GLP-1 therapy, who are at the highest risk for weight regain [13] - The company remains confident in the ongoing pivotal study's power to demonstrate efficacy, with a sample size of 315 patients [26] Conclusion Fractyl Health is advancing its Revita product through promising clinical data and strategic regulatory discussions, positioning itself for a significant impact in the obesity treatment market. The upcoming year is expected to be catalyst-rich, with critical data and regulatory milestones on the horizon [67]

Core Insights - SeaStar Medical Holding Corporation is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life [1][3] - The company will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 5, 2026 [1] - SeaStar Medical's QUELIMMUNE (SCD-PED) therapy is the first commercial product based on its patented Selective Cytopheretic Device (SCD) technology, approved by the FDA in 2024 [3] Company Overview - SeaStar Medical is a commercial-stage healthcare company targeting critically ill patients with organ failure [3] - The QUELIMMUNE (SCD-PED) therapy is the only FDA-approved treatment for life-threatening acute kidney injury (AKI) due to sepsis in critically ill pediatric patients [3] - The Selective Cytopheretic Device (SCD) therapy has received Breakthrough Device Designation for six therapeutic indications, facilitating a faster approval process and better reimbursement dynamics [3] Clinical Trials - The company is conducting the NEUTRALIZE-AKI pivotal trial for its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT) [3] - This condition affects over 200,000 adults in the U.S. annually and currently has no effective treatment options [3]

Core Viewpoint - The collaboration between BD and Envetec has successfully demonstrated a feasible method for recycling polystyrene Petri dishes and other plastics used in healthcare, paving the way for sustainable practices in the industry [1][4]. Group 1: Recycling Feasibility - A joint feasibility study has shown that polystyrene, polyester (PET), polypropylene, and polyethylene can be recycled into high-quality manufacturing feedstock after proper disinfection and processing [2][3]. - Envetec's GENERATIONS® technology effectively converts regulated waste into recyclable polymer flakes through a low-energy chemical disinfection process, enabling the transformation of medical waste into new products [3][8]. Group 2: Industry Impact - The pilot project represents a significant step towards creating sustainable solutions for healthcare supply chains, allowing for the recovery and recycling of various plastic products [4][5]. - BD emphasizes the importance of single-use devices made from high-quality plastics in healthcare while acknowledging their environmental impact, indicating a commitment to circular economy solutions for healthcare consumables [5][6]. Group 3: Future Opportunities - Both BD and Envetec see potential for expanding the pilot project to reduce reliance on virgin plastics and maintain high-value polymers in circulation [4][6]. - Envetec is actively developing sustainable circular pathways for treated laboratory plastics, aiming to convert clean flakes into recycled pellets and new plastic products [6][8].

"嗡——"前几天的一个下午，西湖大学医学院附属杭州市第一人民医院吴山院区（杭州市肿瘤医院）微 创手术室里通明寂静，只有超声及消融仪器的轻微蜂鸣。68岁的张平（化名）平躺在手术台上，脖颈处 贴着无菌膜。 "别怕，全程清醒，就像做一次超声检查。"超声影像科副主任（主持工作）徐陈柯的声音透过口罩传 来，手中的穿刺针在超声屏幕的实时引导下，缓缓刺入他右侧脖颈处的甲状腺。屏幕上，一个直径5.6 毫米微小乳头状癌的轮廓被彩色标记清晰勾勒。 "开始热消融。"随着指令下达，射频电流通过针尖释放，瞬间的高温让肿瘤细胞凝固坏死。张平只感觉 到颈部有轻微的温热感，短短几分钟后，手术结束，穿刺点仅留下一个米粒大小的创口。当天下午，他 便办理了出院手续。 "原本以为要开大刀留疤痕，还得终身吃药，没想到一根针就解决了。"术后复查看着报告上"病灶无活 性"的结论，张平难掩激动。 近年来随着技术的日新月异，微创介入治疗已从单一的局部治疗，升级为"局部+系统"的综合治疗模 式。胡红杰教授介绍，浙大邵逸夫医院在临床实践中，就成功将消融技术与血管栓塞、化疗栓塞、靶向 治疗、免疫治疗等手段有机结合，可量身定制个性化治疗方案。如针对直径＞5厘米的大肿 ...